BEIJING, March 16, 2011 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based advanced in-vitro diagnostic ("IVD") company, today announced that it will meet investors at the following investor conferences and events:
Investor Conference and Event
UBS Greater China Healthcare Corporate Day
March 28, 2011
Morgan Stanley China Healthcare Investor Day
March 28, 2011
Macquarie Greater China Conference
May 12-13, 2011
BNP Paribas "China Equities - The Final Frontier" Conference
June 20-21, 2011 June 23, 2011
London New York
The Company's management will attend these investor conferences and events and discuss the Company's strategies, operations, growth opportunities as well as its published financial results to date with investors.
About China Medical Technologies, Inc.
China Medical Technologies, Inc. is a leading China-based advanced IVD company using molecular diagnostic technologies including Fluorescent in situ Hybridization (FISH) and Surface Plasmon Resonance (SPR) and an immunodiagnostic technology, Enhanced Chemiluminescence Immunoassay (ECLIA), to develop, manufacture and distribute diagnostic products used for the detection of various cancers, diseases and disorders as well as companion diagnostic tests for targeted cancer drugs. The Company generates all of its revenues in China through the sale of diagnostic consumables including FISH probes, SPR-based DNA chips and ECLIA reagent kits to hospitals which are recurring users of the consumables for their patients. The Company sells FISH probes and SPR chips to large hospitals through its direct sales personnel and ECLIA reagent kits to small and mid-size hospitals through distributors. For more information, please visit http://www.chinameditech.com.
SOURCE China Medical Technologies, Inc.